Oseltamivir-resistant pandemic H1N1 influenza

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 7, 2011, Pages

  Webster, Duncan ^a   Li, Yan ^c   Bastien, Nathalie ^c   Garceau, Richard ^d   Hatchette, Todd F ^b  

^a SAINT JOHN REGIONAL HOSPITAL   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d Hôpital Dr G L Dumont   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; AUTOPSY; CASE REPORT; DEATH; DETERIORATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALE; NOSE SMEAR; PANDEMIC INFLUENZA; PRESCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROAT CULTURE;

EID: 79955161594     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.100313     Document Type: Article

References (12)

1. Public Health Agency of Canada. Flu Watch: April 25 to May 1, 2010 (Week 17). Ottawa (ON): The Agency; 2010. Available: www.phac-aspc.gc.ca/fluwatch/09- 10/w17-10/index-eng.php (accessed 2010 June 29).
2. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Atlanta (GA): The Center; 2010. Available: www.cdc.gov/h1n1flu/recommendations.htm (accessed 2010 June 7).
3. Public Health Agency of Canada. Clinical recommendations for patients presenting with respiratory symptoms during the 2009-2010 influenza season. Ottawa (ON): The Agency; 2010. Available: www.phac-aspc.gc.ca/alert-alerte/h1n1/ pdf/H1N1-DecisionTreeoct23-e.pdf (accessed 2010 June 7).
4. Baum SG. Oseltamivir-resistance: What does it mean clinically? Clin Infect Dis 2009;49:1836-7.
5. World Health Organization. Weekly update on oseltamivir resistance to influenza A (H1N1) 2009 viruses. Geneva: The Organization;2010 Available: www.who.int/csr/disease/influenza/2011-01- 28weeklywebupdateoseltamivirresistance.pdf (accessed 2011 Feb. 5).
6. Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivirresistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009;361:2296-7.
7. Canadian Public Health Laboratory Network. Interim guidance for laboratory testing for detection and characterization of pandemic H1N1 (2009) virus. Winnipeg (MB): The Network; 2009. Available: www .cphln.ca/pubs-best- practices-eng.html (accessed 2010 June 8).
8. Canadian Public Health Laboratory Network. Guidance for laboratory testing for detection and characterization of human influenza virus for the 2010-2011 respiratory virus season. Winnipeg (MB): The Network; 2010. Available: www.cphln.ca/documents/EN-influenza-seasonal best practices 2010-2011.pdf (accessed 2011 Feb. 5).
9. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72. (Pubitemid 41817715)
10. Moscona A. Oseltamivir resistance - Disabling our influenza defences. N Engl J Med 2005;353:2633-6. (Pubitemid 41817709)
11. World Health Organization. Global circulation of influenza viruses. Geneva: The Organization; 2011. Available: www.who.int/csr/disease/influenza/ 2011-01-28-influenza-global-circulation.pdf (accessed 2011 Feb. 4).
12. Public Health Agency of Canada. FluWatch: January 16 to 22, 2011 (Week 03). Ottawa (ON): The Agency; 2011. Available: www.phac-aspc.gc.ca/fluwatch/10- 11/w03-11/pdf/fw2011-03-eng.pdf (accessed 2011 Feb. 4).